ADIAL PHARMACEUTICALS, INC. current report, 19 June 2019

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Adial Pharmaceuticals, Inc. on June 19, 2019. The registrant is a Delaware corporation with principal executive offices in Charlottesville, Virginia. The report primarily announces the scheduling of the Company's 2019 Annual Meeting of Stockholders and establishes deadlines for shareholder proposals and director nominations.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural report regarding corporate governance events and does not contain financial statements or performance data.

Material Changes

No material financial changes or operational updates are reported in this filing. The document notes that the Company did not hold an Annual Meeting of Stockholders in 2018, necessitating the specific procedural deadlines outlined for the 2019 meeting.

Guidance, Outlook, and Corporate Events

  • 2019 Annual Meeting: Scheduled for August 16, 2019, at 9:00 a.m. Eastern Time, at the Company's headquarters in Charlottesville, Virginia.
  • Record Date: Stockholders of record as of the close of business on June 25, 2019, are entitled to vote.
  • Proposal Deadlines:
    • Rule 14a-8 Proposals: Must be received by 5:00 p.m. Eastern Time on June 28, 2019, to be included in proxy materials.
    • Director Nominations/Other Business: Written notice must be received by the Corporate Secretary by 5:00 p.m. Eastern Time on June 28, 2019.
  • Compliance: All proposals must comply with Delaware law, SEC rules, and the Company's Bylaws.

Investor Verification Checklist

  • Verify the record date of June 25, 2019, to confirm voting eligibility.
  • Confirm the deadline of June 28, 2019, for submitting any shareholder proposals or director nominations.
  • Review the Company's Bylaws and SEC Rule 14a-8 requirements to ensure any proposed business meets inclusion criteria.
  • Note that no financial performance data is contained in this specific filing; refer to recent 10-K or 10-Q filings for financial metrics.